Full text is available at the source.
Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk
Risk of optic nerve damage linked to semaglutide varies by sex and drug form
AI simplified
Abstract
Among 31,774 cases, Wegovy is associated with a 74.89 reporting odds ratio for ischaemic optic neuropathy compared to Ozempic at 18.81.
- Ischaemic optic neuropathy (ION) is linked to GLP-1 receptor agonists, especially semaglutide.
- Men show a higher risk for ION, with a reporting odds ratio of 116.37.
- Multivariable regression indicates that Wegovy poses a greater risk for ION than Ozempic, with an adjusted odds ratio of 4.74.
- The findings suggest a potential dose-dependent safety concern that needs further investigation.
AI simplified